cyrilzakka/clinical-trials huggingface dataset:
Contrast Ultrasound Perfusion Imaging in PAD With Sonazoid

The measurement of limb skeletal muscle perfusion and perfusion reserve during exercise is an approach that can assess the total impact of the complex pathophysiologic processes in patients with limb ischemia, particularly in those with diabetes in whom distal arterial disease and abnormal microvascular functional responses are common. This trial is designed to: (a) optimize methods for assessment of limb perfusion at rest and during stress using contrast-enhanced ultrasound (normal subjects) and a microbubble contrast agent that is able to provide non-linear signal without destruction at medium acoustic pressures, and (b) to test whether perfusion imaging provides incremental information on the severity of disease in patients with peripheral artery disease.


Eligibility Criteria:
Inclusion Criteria:

* For Healthy controls: no active major medical problems or vasoactive medications
* For PAD: Known diagnosis with PAD an ABI of 0.4-0.6

Exclusion Criteria:

* Rutherford class 6 or greater
* Allergy to ultrasound contrast agents
* Previous limb amputation
* Pregnancy
* Known congenital or acquired right to left shunt
Comparison Between Intraligamentary Piroxicam and Articaine

Comparing the efficacy of intra-ligamentary Piroxicam and intra-ligamentary Articaine on pain during and after endodontic treatment of mandibular molars with symptomatic irreversible pulpitis.

Owing to the painful nature of endodontic treatment in teeth with symptomatic irreversible pulpitis and difficulty in achieving effective anesthesia particularly in mandibular molars due to various factors such as different bony landmarks, anatomical variations, needle deflection, accessory innervation, so local anesthesia isn't enough in such cases. Piroxicam is a long-acting potent analgesic non selective oxicams derivative, has a half-life of 50 hrs in the plasma.The onset of action of oral Piroxicam is 2-4 hrs, but it is anticipated that injectable piroxicam could produce more rapid onset of action. It could favourably overcome the intense pain up to 48 hrs following the treatment. It is also postulated that the intraligamentary injection enables the application of anti-inflammatory agents in the periapical intraosseous region. Moreover, intra-ligamentary injection of local anesthesia was reported to be an effective and easy way to control severe pain during endodontic treatment mainly in mandibular teeth which are more difficult than maxillary teeth , thus piroxicam may be effective as an adjuvant drug to support the action of local anesthetics.

Eligibility Criteria:
Inclusion Criteria:

* Healthy and medically free patients.
* Acute symptomatic irreversible pulpitis of the mandibular first or second molar teeth.
* Vital teeth with no history of previous root canal treatment.
* Teeth that could be treated endodontically in single visit.
* Teeth with normal periodontium, not sensitive to percussion with no periapical radiolucency.
* Patients able to understand numerical rating scale and sign the informed consent.

Exclusion Criteria:

* Known hypersensitivity to piroxicam.
* Pregnancy or lactation.
* Asthma or allergy to other anti-inflammatory drugs.
* History of peptic ulceration.
* Teeth associated with swelling or fistulous tract, acute or chronic periapical abscess.
Evolution of the Patient's Perception of the Use of the Upper Limb After a Stroke During Intensive Rehabilitation

This study is being carried out in the context of rehabilitation after stroke, where persistent upper limb weakness is a major challenge. It aims to explore the relationship between observed function and patients' perceived participation in use.


Eligibility Criteria:
Inclusion Criteria:

* First stroke as defined by the World Health Organization.
* Upper limb paresis with a NIHSS National Institutes of Health Stroke Scale score \> or = 1/4 for upper limb motor function

Exclusion Criteria:

* Life expectancy \<12 months
* Inability to understand French.
* Pre-existing severe multiple disability affecting arm function.
* Presence of pre-existing central neurological pathologies.
* Mini-Mental State Examination \< 21
Safety and Immunogenicity of MSB11455 in Healthy Participants

The primary purpose of this study is to compare the immunogenicity and safety of MSB11455 and Neulasta in healthy adult participants.


Eligibility Criteria:
Inclusion Criteria:

* Participants who provide signed and dated written informed consent.
* Participants with laboratory test results within predefined ranges.
* Other protocol defined inclusion criteria could apply.

Exclusion Criteria:

* Participants with known hypersensitivity to any component of US-Neulasta or MSB11455.
* Other protocol defined exclusion criteria could apply.
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)

To identify factors that signal the transition from asymptomatic (preclinical) to symptomatic Alzheimer disease (AD).

The purpose of this research study is to evaluate the structure and function of the brain in healthy aging and early Alzheimer's disease using positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT) imaging. The study involves imaging the brain to detect the presence of amyloid deposits (plaques in the brain). Amyloid is a protein that may be related to dementia of Alzheimer's disease (DAT).

This study will use radioactive tracers called C-11 Pittsburgh Compound B (PIB) and F 18/ AV-1451 (Flortaucipir) which binds to beta amyloid and tau in the brain. These compounds are considered investigational, which means that they have not been approved by the United States Food and Drug Administration (FDA).

Eligibility Criteria:
Inclusion Criteria:

* Male or female, any race
* Age \> 18 years
* Participation in one of the ongoing projects affiliated with the Knight ADRC at Washington University and referred by the MAP staff and a Washington University physician.
* Normal cognition or early-stage symptomatic AD
* Willing and able to undergo study procedures.
* Capacity to give informed consent and follow study procedures

Exclusion Criteria:

* Has any condition that, in the Investigator's opinion, could increase risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data (e.g., participants with severe chronic back pain might not be able to lie still during the scanning procedures);
* Has hypersensitivity to either AV-1451 or PIB or any of its excipients;
* Contraindications to PET, CT or MRI (e.g. electronic medical devices, inability to lie still for extended periods) that make it unsafe for the individual to participate;
* Severe claustrophobia;
* Currently pregnant or breast-feeding. Women must agree to avoid becoming pregnant and must agree to refrain from sexual activity or to use reliable contraceptive methods for 24 hours following administration of Flortaucipir injection;
* Must not have participated in any clinical trial involving a study drug or device within the 30-days prior to study enrollment;
* Must not participate in another drug or device study prior to the end of this study participation;
* Current or recent (within 12 months prior to screening) participation in research studies involving radioactive agents such that the total research-related radiation dose to the participant in any given year would exceed the limits set forth in the U.S. Code of Federal Regulations (CFR) Title 21 Section 361.1.

https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=361.1
Impact of Semi-automated Proposal and Optimization of Diagnoses and Surgical Procedures for Precoding: a Randomized Controlled Trial

The hypothesis of present study is that the daily monitoring and optimization of DRG coding is associated with higher reimbursement. Therefore, the primary objective is to determine if the daily monitoring and optimization of DRG coding of individual cases leads to better proceeds per day.


Eligibility Criteria:
Inclusion Criteria:

* patients undergoing surgery as inpatients (at least one night stay)
* treated at the Kantonsspital St. Gallen, St. Gallen site

Exclusion Criteria:

* surgery as outpatients
* surgery at the Rorschach and Flawil sites
* patients operated on by the Department of Surgery, but hospitalized at another department of the hospital
Clinical Assessment of Perfusion Techniques During Repair of Coarctation With Aortic Arch Hypoplasia in Infants

The purpose of this study is to evaluate safety and efficacy of three main perfusion methods in surgical repair of coarctation of aorta with aortic arch hypoplasia in infants.

Three perfusion techniques of visceral protection will be assessed - deep hypothermic circulatory arrest, selective antegrade cerebral perfusion and double arterial cannulation (perfusion of brachiocephalic artery with thoracic descending aorta by two arterial cannulas)

Eligibility Criteria:
Inclusion Criteria:

* coarctation with severe aortic arch hypoplasia (distal aortic arch z-score \< -2)
* coarctation of aorta with septal defects

Exclusion Criteria:

* coarctation with mild aortic arch hypoplasia (distal aortic arch z-score \> -2)
* complex congenital heart diseases including aortic arch hypoplasia (e.g. transposition of great arteries, double oulet right ventricle, atrioventricular septal defect, Shone's complex)
* univentricular and duct-dependent heart defects
* aortic valve and/or mitral valve stenosis/hypoplasia (aortic valve or mitral valve z-score \< -2.0)
* left ventricular dysfunction (left ventricle ejection fraction \< 60%)
* congenital renal or central nervous system anomalies
* related infectious diseases
* prematurity (gestational age \< 37 weeks)
Dexamethasone with Ropivacaine for PENG Block in Total Hip Arthroplasty

Does adding Dexamethasone to the Periarticular Nerve Group Block in Patients undergoing Total Hip Arthroplasty reduce the dose of ropivacaine?

Hip arthroplasty is one of the most common orthopaedic procedures, especially in elderly patients, due to the deformation of joints. Patients may complain of severe pain due to surgical trauma and prostheses. Regional anaesthesia methods may be performed to reduce the inflammatory response, opioid consumption, and opioid-related side effects.

Eligibility Criteria:
Inclusion Criteria:

* patients scheduled for total hip arthroplasty
* patients aged \>65 and \<100 years
* patients able to provide informed consent
* patients able to reliably report symptoms to the research team

Exclusion Criteria:

* inability to provide first-party consent due to cognitive impairment or a language barrier
A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes

This study will be conducted in participants with type 1 diabetes mellitus on continuous subcutaneous insulin infusion (CSII) or pump therapy to evaluate the effect of LY900014 (Lyumjev) on blood sugar levels during exercise using different approaches on basal rate reduction and following a test meal compared to insulin lispro (Humalog). The study may last up to approximately 10 weeks and may include up to 7 visits.


Eligibility Criteria:
Inclusion Criteria:

* Male or female participants with type 1 diabetes
* Body mass index (BMI) between 18.5 and 29.0 kilograms per square meter (kg/m²), inclusive
* Hemoglobin A1c (HbA1c) less than or equal to 8.5 percent (%)
* Using CSII and stable insulin regimen for at least 6 months prior to inclusion into the trial
* Able to undergo at least 1 hour of moderate-intensity exercise

Exclusion Criteria:

* Are currently participating or recently participated in a clinical trial or any other type of medical research judged to be incompatible with this study
* Have a blood loss of more than 500 milliliters (mL) within the last month
* Have known allergies to insulin lispro, related compounds or any components of the study drug formulation
* Have previously participated or withdrawn from this study
* Have or used to have health problems or medical test results that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
* Participants who have an abnormal blood pressure and/or pulse rate
* Participants with clinically significant cardiac or pulmonary disease
Current Practices of Upper Limb Rehabilitation After Stroke

A survey was conducted among physiotherapists and occupational therapists working with stroke patients. The survey consisted out of 30 questions enquiring personal information and upper limb specific topics divided in 3 sections: (1) Passive mobilization, (2) Active exercises and (3) Immobilization. The survey took approximately 20 to 30 minutes to complete.

The survey for stroke survivors was divided in seven sections: (1) Personal information (2) Motor recovery of the upper limb and expectations on upper limb recovery; (3) Comfort, pain and quality of life (QoL); (4) Immobilization ; (5) Physiotherapy; (6) Occupational therapy; (7) Nursing (only for patients less than 6 months after stroke). The length to complete the survey was also organized to be achieved in 20 to 30 minutes.


Eligibility Criteria:
Stroke patients

Inclusion Criteria:

* stroke with upper limb paresis

Exclusion Criteria:

* severe language or cognitive problems which make it impossible to complete the survey

Therapists

Inclusion Criteria:

* physiotherapists
* occupational therapists
* experienced in the treatment of stroke patients
2% Lidocaine Plus 0.5% Bupivacaine Versus 0.5% Bupivacaine in Brachial Block for Creation of Arteriovenous (AV) Fistula

Will the technique of adding lidocaine to bupivacaine fasten the onset of bupivacaine alone for infraclavicular brachial plexus block in end-stage renal disease (ESRD) patient?


Eligibility Criteria:
Inclusion Criteria:

* ESRD patient for AVF procedure
* age \>17 year
* BMI 20-35 kg/m2
* communicable

Exclusion Criteria:

* BMI \> 35 kg/m2 BMI \< 20 kg/m2 หรือ BW \< 35 kg
* History of allergy to local anesthetic drugs
* Pre-operative neurological deficit, Neuromuscular disorder หรือ old CVA
* Psychiatric disorder
* Coagulation disorder
* Uncontrolled seizure
* Pregnant and lactating women
Early Treatment of Skeletal Anterior Open Bite by Two Appliances

Open bite is a common dentoalveolar component of the facial pattern of the excessive vertical dimension patients that is also known as the gaping angle face pattern.It is a deformation in the vertical relationship between the upper and the lower dental arches that is characterized by the loss of contact between the opposite dental segments.

An open bite develops as a result of the interaction of many etiologic factors, both hereditary and environmental. Prolonged sucking habits and hyper-divergent facial characteristics are significant risk factors for an anterior open bite in the mixed dentition. Abnormal tongue posture (frequently associated with enlarged adenoids or tonsils) and tongue thrust also can be involved in the establishment of alveolar and skeletal discrepancies concurrent with vertical problems Two types of an open bite are recognized in this profession: (1) dentoalveolar open bite: the abnormality formalities aspects limiting in the dental and alveolar region, usually associated with abnormal function habits as the thumb sucking and (2) Skeletal open bite: that's associated with an over high of the lower facial vertical dimension and a large plane angle of the lower jaw. open bites associated with excessive vertical skeletal dimensions are difficult to treat and tend to relapse The investigators must be recognized between the dentoalveolar open bite and the open bite caused by formalities disorders and the position disorders of the upper or the lower jaw or both. Dental an open bite can be corrected by itself if the treatment was beginning early and it's responding Easley to the mechanical treatment methods and the functional treatment approaches that depending on the muscular activity

Eligibility Criteria:
Inclusion Criteria:

* Anterior open bite (2-10) mm.
* Skeletal Class I or II malocclusion.
* MP-SN angle ranged between (33-45) degrees.
* MM angle ranged between (27-37) degrees.
* Age between 7.5-10.5 years.

Exclusion Criteria:

* Patients who had an old orthodontic treatment
* People with a syndrome or congenital deformity
Palifermin for Patients Receiving Hematopoietic Stem Cell Transplantation

The purpose of this study is to compare the efficacy and safety of palifermin on reducing mucositis for patients receiving autologous or allogeneic stem cell transplantation with supportive care.


Eligibility Criteria:
Inclusion Criteria:

* adequate organ function
* patients who will receive autologous stem cell transplantation
* patients who will receive allogeneic stem cell transplantation using myeloablative conditioning regimen

Exclusion Criteria:

* presence of concomitant malignancy
* presence of active infection or oral mucositis prior to stem cell transplantation
* any conditions where the severity of oral mucositis cannot be evaluated
Hematopoietic Stem Cell Transplantation for the Treatment of Limb Ischemia and Diabetic Neuropathy

Several pathophysiological theories have been proposed for the development of diabetic chronic complications. In recent years, the use of stem cells (totipotential, hematopoietic or endothelial lineages) has been reported as an adjunctive modality of treatment for ischemia models in animals and humans. Nevertheless, there are no reports in the use of stem cells for the treatment of human sensorimotor peripheral diabetic neuropathy. We performed this study to evaluate the effect of autologous hematopoietic CD34+ cell transplantation on nerve conduction velocity in patients with type 2 diabetes mellitus.


Eligibility Criteria:
Inclusion Criteria:

* Ambulatory patients with type 2 diabetes mellitus and ischemia of one or both lower limbs, defined as lack of limb improvement with conventional care (medications, debridements) after a recent amputation or a patient graded III or IV in the Leriche-Fontaine functional classification.

Exclusion Criteria:

* Patients older than 75 years
* Hypercoagulable states
* Cardiac ejection fraction \< 30%
* Active vasculopathy in brain, kidneys or heart
* Neoplastic disease
* Active infection
* Diabetic ketoacidosis or hyperosmolar hyperglycemic state
* Gangrene of the extremity requiring immediate surgery.
Expanding Use of CGM in Critical Care: Impact on Nurse Work Patterns and Patient Outcomes

The primary objective of this implementation study is to assess the feasibility of real time continuous glucose monitoring (CGM) implementation using a CGM plus (+) point-of-care (POC) protocol among patients on IV insulin or those with hyperglycemia (\>250mg/dl) in the critical care hospital environments.

This study analyzes the feasibility of inpatient real time CGM implementation through the use of a CGM + POC protocol as routine care for glycemic monitoring among patients on IV insulin or those with hyperglycemia (\>250mg/dl). The investigators will examine the effects on medical intensive care (MICU) patient's (N=100) glycemic control compared to matched historical control patients (N=100) from the MICU who received fingerstick POC.

Eligibility Criteria:
Inclusion Criteria:

* adults \>18 years old,
* admitted to Ohio State University Wexner Medical Center MICU and
* have hyperglycemia (glucose \>250mg/dl) or are currently on IV insulin.

Exclusion Criteria:

* Current COVID-19 infection,
* Refractory shock (Levophed dose \>0.5 mcg/kg/min or equivalent)
* Actively being treated for diabetic ketoacidosis (DKA)
* Actively being treated for hyperosmolar non-ketoacidosis (HONK)
* Pitting edema, anasarca, blue or purple discoloration to left upper extremity
* Treated with high dose acetaminophen (\>1 gram Q6 hours)
* Treated with hydroxyurea
* Are pregnant, patients
* Using home insulin pump therapy during hospitalization, or
* Reside in a corrections institution.
Early Diagnosis of Pulmonary Fibrosis - Diagnostic Delay

Patients with newly diagnosed IPF are investigated for the diagnostic delay before a diagnosis of IPF is made.

Pulmonary fibrosis can be secondary to connective-tissue disease, environmental exposure, or drug toxicity, but it can also appear sporadically without any known cause, i.e. idiopathic interstitial pneumonitis (IIP). Idiopathic pulmonary fibrosis (IPF) is the commonest IIP and usually follows a rapidly progressive course with a short median survival time.

IPF is often diagnosed after a long diagnostic delay, which also affects the prognosis. As new anti-fibrotic treatments have been approved, and awareness of IPF is rising, the diagnostic delay and its implications can be expected to be changing. Also, the new diagnostic guidelines of 2011 could change the diagnostic delay. In order to reduce the diagnostic delay, it is important to investigate the health care utilization and decisions made by healthcare professionals in the period before the final diagnosis is made.

This study will prospectively include all patients at the two centres in Denmark where patients are treated for IPF and has thus a good opportunity to include the majority of incident cases of IPF in Denmark. Patients are included immediately after the diagnosis which reduces recall bias. The database will include both patient reported data and objective data from national registries and patient records. A main focus is the distribution of the diagnostic delay between patient and different health care providers, and the health care utilization by the patients before a diagnosis of IPF is made. Risk factors for a delayed diagnosis are investigated. The importance of the diagnostic delay for the prognosis and the course of the disease will also be investigated.

The database created in this study will also be used for future research in IPF.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of IPF according to international guidelines

Exclusion Criteria:

* Unable to provide written informed consent
* Age below 18 years
Innovative Tool to Increase Completion of Human Papillomavirus (HPV) Vaccine Series

Planned Parenthood Federation of America's (PPFA) Medical Affairs Division will conduct a prospective, cluster randomized trial to determine which factors influence the acquisition of the second and third human papillomavirus (HPV) vaccine doses among young women ages 19 to 26. This descriptive and interventional study will provide data to assess impact of a computerized tool upon HPV vaccine series completion. The interventional aspect of this study includes determination of patient assistance and provider support programs applicable to each woman's situation as well as the implementation of a computer software system for customized patient reminders.


Eligibility Criteria:
Inclusion Criteria:

* Female;
* Age 19-26;
* Fluent in English;
* Seeking services for anything except pregnancy or abortion on the day of the visit
* No previous vaccinations for HPV
* No contraindication for HPV vaccine (includes a severe allergic reaction to yeast, amorphous aluminum hydroxyphosphate sulfate, and polysorbate 80.)
* Access to phone, text, mail, email, or facebook
* Not wanting to become pregnant in the next 8 months;
* Not planning on moving from the area in the next 8 months
* Willing to be contacted for follow-up over the next 8 months.

Exclusion Criteria:

* Women below 19 or above 26.
* Male
* Women who have one or more of HPV vaccination.
* Women who have a contraindication for HPV vaccine.
* Women who do not have access by phone, mail, email, Twitter or Facebook for follow up.
* Women who are not fluent in English
* Pregnant women or those intending on becoming pregnant during the study period.
* Women who will be moving from the area and unable to return for follow up over the course of the study (approximately 8 months).
* Severe mental impairment and unable to give Informed Consent.